trem 2

TREM2 agonist-2 (I-192) is an orally efficient small molecule agonist specifically targeting TREM2, serving as a highly potent triggering receptor expressed on myeloid cells 2 (TREM2) agonist, employed in neurodegenerative disease research.

TREM2 agonist-1 (I-246) is a triggering receptor expressed on myeloid cells-2 (TREM2) agonist with an EC50 ranging from 3.0 μM to 100 μM.

rel-5-(4-Chloro-2-fluorophenyl)-2,3-dimethyl-7-[(2R,4S)-tetrahydro-2-(1-methyl-1H-pyrazol-4-yl)-2H-pyran-4-yl]pyrido[3,4-b] The EC50 value of pyrazine against TREM2 was ≤ 0.05 μM and the E.max value was > 250 μM.

TREM2 agonist-3 (Compound 4i) is a direct TREM2 agonist (Kd=19.0 µM), and its Kd value for TREM1 is 39.8 µM. It induces Syk phosphorylation and enhances microglial cell phagocytosis, and can be used for the study of neurodegenerative diseases.

TREM2 agonist-4 (Compound 4a) is a TREM2 agonist with a Kd value of 45.9 μM. It activates the TREM2 downstream signaling pathways and enhances the phagocytic function of microglia. TREM2 agonist-4 is applicable for research into neurodegenerative diseases such as Alzheimer's disease.

TREM2 agonist-5 is a ligand for the microglial lipid-sensing receptor (TREM2) and acts as an agonist with a Kd of 71.36 μM. It is the racemic analog of the TREM2 agonist VG-3927 and demonstrates excellent microglial phagocytic activity in HEK293-hTREM2/DAP12 cells, effectively activating TREM2 signaling. TREM2 agonist-5 has superior in vitro pharmacokinetics compared to VG-3927 and is potentially useful for Alzheimer's disease research.

TREM2-IN-1 (OPA) is a platinum-based TREM2 inhibitor with anti-cancer activity, blocking DNA replication and inhibiting TREM2 on myeloid cells. It suppresses immune regulatory activity, reducing CD206 and CX3CR1 in a mouse model of colorectal cancer.

Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody targeting TREM2.

PY314 is a CHO-expressed humanized monoclonal antibody targeting TREM2 with antitumor activity for the study of metastatic renal cell carcinoma.

IA9 (human TREM-2 182-190) is a TREM-2 inhibitor that can reduce the release of pro-inflammatory factors in collagen-induced arthritis mice, effectively suppressing joint inflammation and damage.

IA9 TFA (human TREM-2 182-190 TFA) is a TREM-2 inhibitor that reduces the release of pro-inflammatory cytokines in mice with collagen-induced arthritis, significantly suppressing joint inflammation and damage.

VGL101 is a human IgG1 monoclonal antibody (mAb) that targets TREM-2. It acts as a pSYK agonist with an EC50 of 0.77 nM. Under ALSP pathological conditions, VGL101 enhances the survival of microglia and monocyte-derived macrophages, inhibits apoptosis, and aids in restoring cell morphology to resemble the normal activated CSF1R state. It is applicable in leukoencephalopathy research. Recommended isotype control: Human IgG1 kappa, Isotype Control.

DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) that targets TREM-2. It is utilized in Alzheimer's disease research. The recommended isotype control is Human IgG1 kappa, Isotype Control.

EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. It has the ability to reprogram TREM2+ macrophages, significantly hindering their tumor-promoting activities and overcoming drug resistance. In mouse models with orthotopic 4T1 triple-negative breast cancer, EOS006215 reduces metastatic burden. Additionally, it notably inhibits tumor growth in anti-PD-1 resistant mouse models. EOS006215 is applicable for studies on triple-negative breast cancer (TNBC).